

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



創美·CH'MEI

**CHARMACY PHARMACEUTICAL CO., LTD.**

創美藥業股份有限公司

*(A joint stock limited liability company established in the PRC)*

**(Stock Code: 2289)**

**GRANT OF WAIVER FROM STRICT COMPLIANCE WITH  
THE MINIMUM PUBLIC FLOAT REQUIREMENT**

References are made to (i) the composite offer and response document jointly issued by Jiangzhong Yishang, the Offeror and the Company dated 20 January 2023 (the “**Composite Document**”); (ii) the announcement jointly issued by Jiangzhong Yishang, the Offeror and the Company dated 10 February 2023 in respect of, among other things, the close of the Offer; and (iii) the announcement jointly issued by Jiangzhong Yishang, the Offeror and the Company dated 16 February 2023 in respect of, among other things, the results and settlement of the Offer (the “**Offer Results Announcement**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Composite Document.

As disclosed in the Offer Results Announcement, immediately after the close of the Offer and upon the completion of the transfer to the Offeror of the Acceptance Shares, 23,343,500 Shares, representing approximately 21.62% of the entire issued share capital of the Company as at the date of the Offer Results Announcement were held by the public (as defined under the Listing Rules). Accordingly, the minimum public float requirement of 25% under Rules 8.08(1)(a) and 13.32(1) of the Listing Rules is not satisfied. The Company has been informed by the Offeror that the Offeror intends to take appropriate steps to ensure that the public float will be restored by disposing of not less than 3,656,500 Shares (the “**Disposal**”), representing approximately 3.38% of the entire issued share capital of the Company as at the date of this announcement, subject to (i) the dealing restrictions of directors under Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules; and (ii) the formal approval from Jiangxi State-Owned Capital Operation Holdings Group Co. Ltd\* (江西省國有資本運營控股集團有限公司) for the Disposal. It is expected that upon completion of the Disposal, the public float of the Company will be restored to no less than 25%. As such, the Company has applied to the Stock

Exchange for a temporary waiver from strict compliance with Rules 8.08(1)(a) and 13.32(1) of the Listing Rules for a period from 10 February 2023 to 10 June 2023 (the “**Waiver Period**”).

On 28 February 2023, the Stock Exchange has granted the Company a temporary waiver from strict compliance with Rules 8.08(1)(a) and 13.32(1) of the Listing Rules during the Waiver Period, subject to the disclosure of the waiver (including details and reasons) by way of publication of this announcement. The Stock Exchange may withdraw or change the waiver if the Company’s situation changes.

Further announcement(s) will be made by the Company regarding the restoration of public float as and when appropriate.

By Order of the Board  
**Charmacy Pharmaceutical Co., Ltd.**  
**Yao Chuanglong**  
*Chairman*

Shantou, the PRC, 1 March 2023

*As at the date of this announcement, the executive Directors are Mr. Yao Chuanglong, Ms. Zheng Yuyan and Ms. Zhang Hanzi; the non-executive Directors are Mr. Li Weisheng, Mr. Yan Jingbin and Ms. Fu Zheng; and the independent non-executive Directors are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).*

*\* For identification purpose only*